- Home
- OBIO vs SKYE Comparison
OBIO vs SKYE Comparison
Compare OBIO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- SKYE
- Stock Information
- Founded
- OBIO 2017
- SKYE 2012
- Country
- OBIO United States
- SKYE United States
- Employees
- OBIO N/A
- SKYE N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- OBIO Health Care
- SKYE Health Care
- Exchange
- OBIO Nasdaq
- SKYE Nasdaq
- Market Cap
- OBIO 205.0M
- SKYE 108.3M
- IPO Year
- OBIO N/A
- SKYE N/A
- Fundamental
- Price
- OBIO $5.83
- SKYE $4.94
- Analyst Decision
- OBIO Strong Buy
- SKYE Buy
- Analyst Count
- OBIO 4
- SKYE 6
- Target Price
- OBIO $15.75
- SKYE $18.67
- AVG Volume (30 Days)
- OBIO 44.2K
- SKYE 308.0K
- Earning Date
- OBIO 11-11-2024
- SKYE 11-09-2024
- Dividend Yield
- OBIO N/A
- SKYE N/A
- EPS Growth
- OBIO N/A
- SKYE N/A
- EPS
- OBIO N/A
- SKYE N/A
- Revenue
- OBIO $2,079,000.00
- SKYE N/A
- Revenue This Year
- OBIO $7.68
- SKYE N/A
- Revenue Next Year
- OBIO $110.40
- SKYE N/A
- P/E Ratio
- OBIO N/A
- SKYE N/A
- Revenue Growth
- OBIO N/A
- SKYE N/A
- 52 Week Low
- OBIO $4.22
- SKYE $1.44
- 52 Week High
- OBIO $11.69
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- OBIO 60.54
- SKYE 58.26
- Support Level
- OBIO $5.20
- SKYE $4.01
- Resistance Level
- OBIO $5.99
- SKYE $5.48
- Average True Range (ATR)
- OBIO 0.38
- SKYE 0.46
- MACD
- OBIO 0.12
- SKYE 0.19
- Stochastic Oscillator
- OBIO 87.20
- SKYE 73.79
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.